LUPIN.NS - Lupin Limited

NSE - NSE Real Time Price. Currency in INR
847.30
+25.65 (+3.12%)
At close: 3:29PM IST
Stock chart is not supported by your current browser
Previous Close821.65
Open815.00
Bid847.30 x 0
Ask0.00 x 0
Day's Range806.20 - 855.00
52 Week Range723.65 - 986.10
Volume4,847,312
Avg. Volume2,087,123
Market Cap382.568B
Beta (3Y Monthly)0.08
PE Ratio (TTM)N/A
EPS (TTM)-2.06
Earnings DateN/A
Forward Dividend & Yield5.00 (0.58%)
Ex-Dividend Date2018-07-30
1y Target Est951.98
  • Reuterslast month

    Lupin second-quarter profit dives as U.S. sales, higher expenses weigh

    (Reuters) - Lupin Ltd, India's second-largest drugmaker by revenue, posted a lower-than-expected second-quarter profit on Wednesday, as sales in the United States - a key market - dropped and overall manufacturing ...

  • GlobeNewswire2 months ago

    Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

    Zug, Switzerland, October 19, 2018: Lupin Neurosciences, a specialty pharma division of Lupin Ltd, today announces that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the marketing authorization of NaMuscla™ (mexiletine hydrochloride) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. Non-dystrophic myotonic disorders are a group of rare, inherited neuromuscular disorders which cause the inability of muscle relaxation following voluntary contraction.

  • India's Lupin first-quarter profit misses estimate by wide margin
    Reuters4 months ago

    India's Lupin first-quarter profit misses estimate by wide margin

    (Reuters) - Drugmaker Lupin Ltd posted a bigger-than-expected fall in first-quarter profit on Wednesday, hurt by declining sales in the United States and Japan. Sanctions imposed by international regulatory ...

  • Reuters4 months ago

    India's Lupin Q1 profit misses estimate by wide margin

    Drugmaker Lupin Ltd posted a bigger-than-expected fall in first-quarter profit on Wednesday, hurt by declining sales in the United States and Japan. Sanctions imposed by international regulatory bodies ...

  • Reuters4 months ago

    India's Lupin quarterly profit falls 43 pct

    Drugmaker Lupin Ltd posted a 43 percent fall in first-quarter profit on Wednesday, widely missing analysts' estimates. Net profit was 2.03 billion rupees in the quarter ended June 30, compared with a profit ...

  • Who Really Owns Lupin Limited (NSE:LUPIN)?
    Simply Wall St.4 months ago

    Who Really Owns Lupin Limited (NSE:LUPIN)?

    In this analysis, my focus will be on developing a perspective on Lupin Limited’s (NSE:LUPIN) latest ownership structure, a less discussed, but important factor. When it comes to ownership structureRead More...

  • Mylan Partners with Lupin to Commercialize Arthritis Biosimilar
    Market Realist6 months ago

    Mylan Partners with Lupin to Commercialize Arthritis Biosimilar

    Today, Mylan (MYL) and Lupin announced that the two companies have entered into a partnership for the commercialization of a biosimilar of Amgen’s (AMGN) Enbrel (etanercept). As per the agreement, Mylan will sell Lupin’s proposed biosimilar of Enbrel in Europe, Latin America, Australia, New Zealand, Africa, and most Asian markets.

  • Mylan, Lupin Collaborate for the Proposed Biosimilar Enbrel
    Zacks6 months ago

    Mylan, Lupin Collaborate for the Proposed Biosimilar Enbrel

    Mylan (MYL) enters a partnership with Lupin Limited to commercialize a biosimilar of blockbuster drug Enbrel on approval.

  • What You Must Know About Lupin Limited’s (NSE:LUPIN) 1.90% ROE
    Simply Wall St.6 months ago

    What You Must Know About Lupin Limited’s (NSE:LUPIN) 1.90% ROE

    This article is intended for those of you who are at the beginning of your investing journey and want to better understand how you can grow your money by investingRead More...

  • Lupin Limited (NSE:LUPIN) Investors Are Paying Above The Intrinsic Value
    Simply Wall St.6 months ago

    Lupin Limited (NSE:LUPIN) Investors Are Paying Above The Intrinsic Value

    I am going to run you through how I calculated the intrinsic value of Lupin Limited (NSEI:LUPIN) using the discounted cash flow (DCF) method. If you want to learn moreRead More...

  • Reuters6 months ago

    Sensex hits over four-month closing high

    (Reuters) - Indian shares rose on Tuesday, in line with broader Asian peers, as sentiment turned upbeat after U.S. President Donald Trump and North Korean leader Kim Jong Un pledged to work towards complete ...

  • Is Lupin Limited’s (NSE:LUPIN) PE Ratio A Signal To Sell For Investors?
    Simply Wall St.6 months ago

    Is Lupin Limited’s (NSE:LUPIN) PE Ratio A Signal To Sell For Investors?

    Lupin Limited (NSEI:LUPIN) is trading with a trailing P/E of 138.9x, which is higher than the industry average of 25.3x. While LUPIN might seem like a stock to avoid orRead More...

  • What Do Analysts Think About Lupin Limited’s (NSE:LUPIN) Earnings Trend?
    Simply Wall St.7 months ago

    What Do Analysts Think About Lupin Limited’s (NSE:LUPIN) Earnings Trend?

    In March 2018, Lupin Limited (NSEI:LUPIN) announced its most recent earnings update, which signalled that the business faced a immense headwind with earnings falling by -90.18%. Below is a briefRead More...

  • Reuters7 months ago

    Lupin expects U.S. drug pricing pressure to ease in 2019

    Last week, Teva Pharmaceutical, the world’s largest generic drugs maker, said it planned to cut back some of the products it sells in the U.S. market. Lupin Chief Executive Vinita Gupta said she hoped Teva’s move would create space for to rival Indian drugmakers like Lupin to grow. “We do believe the worst is over,” Gupta said on a post-earnings media call on Wednesday.

  • Reuters7 months ago

    India's Lupin expects U.S. drug pricing pressure to ease in 2019

    India's second-largest drugmaker Lupin Ltd said on Wednesday it expected pressure on drug prices in the United States, which has hit its profits, to ease this year as larger rivals reduce their exposure there. Last week, Teva Pharmaceutical, the world’s largest generic drugs maker, said it planned to cut back some of the products it sells in the U.S. market. Lupin Chief Executive Vinita Gupta said she hoped Teva’s move would create space for to rival Indian drugmakers like Lupin to grow.

  • Lupin Limited (NSE:LUPIN): Does The Earnings Decline Make It An Underperformer?
    Simply Wall St.8 months ago

    Lupin Limited (NSE:LUPIN): Does The Earnings Decline Make It An Underperformer?

    Analyzing Lupin Limited’s (NSEI:LUPIN) track record of past performance is a valuable exercise for investors. It enables us to reflect on whether or not the company has met expectations, whichRead More...

  • Is Lupin Limited (NSE:LUPIN) A Financially Sound Company?
    Simply Wall St.8 months ago

    Is Lupin Limited (NSE:LUPIN) A Financially Sound Company?

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Lupin Limited (NSEI:LUPIN), with a market capitalization of ₹363.61B, rarely draw their attention from the investing community.Read More...

  • February Stocks Insiders Just Bought
    Simply Wall St.10 months ago

    February Stocks Insiders Just Bought

    Insiders buying more shares in their own company indicates confidence in management’s outlook in the future. Research from MIT suggests stocks that have recently seen insider buying outperformed the marketRead More...

  • Reuters10 months ago

    Lupin third-quarter profit misses estimates on lower sales in North America, forex losses

    Indian pharmaceutical companies have struggled with weak sales in the United States on account of regulatory bans and warnings over quality control violations at production plants. Lupin said its sales in North America, which accounts for more than a third of its total sales, fell 34 percent to 14.32 billion rupees ($223.29 million). Net sales slipped 11.5 percent to 39 billion rupees.

  • Plans to Slash Medical Costs in America Run Into Generic Drug Concerns
    Bloomberg11 months ago

    Plans to Slash Medical Costs in America Run Into Generic Drug Concerns

    As U.S. regulators push hundreds of new generic drugs to market in an effort to drive down prices, the industry is facing a continuing problem in India, where many copycat medicines are manufactured.